Exhibit 99.1

 

 

 

 

 

vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

 

Initiation of Mechanistic Study of TTP399 expected during Q1 2021

 

Announcement of First-Patient First-Visit in Multiple Ascending Dose Phase 1 Study of HPP737

 

Publication of Phase 2 SimpliciT-1 Results of TTP399 in ADA’s Diabetes Care Journal

 

HIGH POINT, N.C. – (GLOBE NEWSWIRE) – February 24, 2021 – vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2020, and provided an update on the progress of its clinical programs.

 

“Despite the challenges of operating through a global pandemic, 2020 was a successful year for vTv Therapeutics,” said Steve Holcombe, president and CEO. “We had positive results in the Phase 2 SimpliciT-1 Study with our lead compound, TTP399, paving the way for our continued development of this asset in patients with type 1 diabetes. In addition, we strengthened our current and future financial position with the initiation of our ATM, agreement with Lincoln Park Capital, and licensing agreement with Anteris Bio.”

 

“In 2021, we look forward to building on these successes as we advance our two lead programs for the treatment of type 1 diabetes and psoriasis. We plan to initiate our first pivotal study of TTP399 along with other supporting studies to demonstrate our unique glucokinase activator’s potential to reduce the incidence of hypoglycemia in people with type 1 diabetes. Furthermore, we have commenced a multiple ascending dose study with HPP737 to be followed by a phase 2 study in patients with psoriasis in order to demonstrate HPP737’s potential to be a well-tolerated, next-generation PDE4 inhibitor.”

 

Recent Achievements and Outlook

 

Type 1 Diabetes

 

 

Mechanistic Study of Ketoacidosis with TTP399.  To further support the hypothesis that TTP399 may help reduce the incidence of ketoacidosis, vTv will begin dosing of a mechanistic study of TTP399 in patients with type 1 diabetes during Q1 of 2021 to determine the impact of TTP399 on ketone body formation during a period of acute insulin withdrawal.  The  FDA agreed with the Company’s recommendation that such a mechanistic study be performed in support of the Company’s planned pivotal trials. vTv expects to report topline results from the mechanistic study in Q2/Q3 2021.

 

 

Pivotal Study Planning.  The Company is planning to initiate the first of two pivotal, placebo-controlled, six-month clinical trials of TTP399 in approximately 400 subjects with type 1 diabetes in 2H 2021.  The studies will be designed to assess TTP399’s ability to reduce the incidence of hypoglycemia when administered as an oral adjunct to insulin therapy.

 

 


 

 

Publication of SimpliciT-1 Results.  Diabetes Care, the American Diabetes Association’s journal of clinical research, published the positive results of the Phase 2 SimpliciT-1 Study of TTP399 as an adjunct therapy to insulin in patients with type 1 diabetes, which showed statistically significant reductions in HbA1c and clinically meaningful reductions in hypoglycemia.

 

Psoriasis

 

 

First-Patient First-Visit of Multiple Ascending Dose Study with HPP737.  The Company has begun dosing of a phase 1 multiple ascending dose study to assess the safety, tolerability, and pharmacokinetic profile of HPP737, a PDE4 inhibitor, in healthy volunteers.  The phase 1 study will inform dose selection for the planned phase 2 study in psoriasis that the Company expects to begin later this year.

 

Strategic Partnership with Anteris Bio

 

 

License Agreement for Nrf2 Activator HPP971. In December 2020, the Company announced a new license agreement with Anteris Bio for worldwide rights to vTv’s novel, clinical-stage Nrf2 activator compound, HPP971.  Anteris will be pursuing indications in renal disease with HPP971.

 

Azeliragon (TTP488)

 

 

Discontinuation of azeliragon for Alzheimer’s disease. On December 15, 2020, vTv announced that the phase 2 Elevage Study of azeliragon did not meet its primary objective.  vTv has discontinued development of azeliragon for Alzheimer’s disease, but the Company is evaluating potential alternative indications in partnership with other interested parties.

 

Capital Raising

 

 

At-the-Market (ATM) Offering.  In January, the Company filed a prospectus supplement for $5.5 million of additional capacity under the Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co.  As of the date of this release, the full $5.5 million remains available.

 

 

Lincoln Park. The Company continues to leverage its partnership with Lincoln Park to raise capital to fund its on-going and planned clinical trials and corporate operations on an opportunistic basis.

 

Fourth Quarter 2020 Financial Results

 

 

Cash Position: The Company’s cash position as of December 31, 2020, was $5.7 million compared to $1.8 million as of September 30, 2020.

 

 

Revenue: Revenue for the fourth quarter was $6.4 million and was insignificant for the third quarter of 2020.  The revenue for the fourth quarter was primarily attributable to the upfront consideration, consisting of cash and an equity interest, received in connection with the Company’s license agreement with Anteris Bio.

 

                                                      


 

 

R&D Expenses: Research and development expenses were $2.5 million and $1.8 million for the three months ended December 31, 2020 and September 30, 2020, respectively.  This increase of $0.8 million was driven primarily by the reversal of certain performance-based compensation accruals which occurred in the third quarter.

 

 

G&A Expenses: General and administrative expenses were $2.0 million for the fourth quarter of 2020 and $1.1 million for the third quarter, respectively. The increase of $1.0 million was driven by the reversal of certain performance-based compensation accruals in the third quarter.

 

 

Net Income/(Loss) Before Non-Controlling Interest: Net income before non-controlling interest was $1.6 million for the fourth quarter of 2020 compared to a net loss of $2.3 million for the third quarter of 2020.

 

 

Net Income/(Loss) Per Share: Diluted net income per share was $0.02 for the three months ended December 31, 2020 compared to a diluted net loss per share of ($0.03) for the three months ended September 30, 2020, based on weighted-average diluted shares of 74.4 million and 48.2 million for the three-month periods ended December 31, 2020 and September 30, 2020, respectively. Non-GAAP net income per fully exchanged share was $0.02 for the three months ended December 31, 2020 compared to a net loss per fully exchanged share of ($0.02) at September 30, 2020, based on non-GAAP fully exchanged weighted-average shares of 74.4 million and 71.3 million for the three months ended December 31, 2020 and September 30, 2020, respectively.

 

Full Year 2020 Financial Results

 

 

Revenue: Revenues were $6.4 million and $2.8 million for the years ended December 31, 2020 and 2019, respectively. The 2020 revenue is attributable to the upfront payment and fair value of the equity interest received by the Company in connection with the license agreement with Anteris Bio.  The revenue earned during 2019 primarily relates to the recognition of amounts deferred for the license agreement with Reneo and a milestone received under the license agreement with Newsoara.

 

 

R&D Expenses: Research and development expenses were $11.0 million and $15.1 million for the years ended December 31, 2020 and 2019, respectively. This decrease was attributable primarily to lower spending on clinical trials for azeliragon and TTP399 in 2020 coupled with the impact of reversals of performance-based compensation accruals in 2020.

 

 

G&A Expenses: General and administrative expenses were $7.3 million and $8.5 million for the years ended December 31, 2020 and 2019, respectively. Such decreases were primarily driven by lower compensation costs related to a reversal of accruals for performance-based compensation and lower share-based compensation expense in 2020.

 

 

Net Loss Before Non-Controlling Interest: Net loss before non-controlling interest was $12.8 million and $21.9 million for the years ended December 31, 2020 and 2019, respectively.

 

 

Net Loss Per Share: GAAP net loss per share was $0.18 and $0.59 for the years ended December 31, 2020 and 2019, respectively, based on weighted-average shares of 47.1 million and 30.3 million for the years ended December 31, 2020 and 2019, respectively. Non-GAAP net loss per fully exchanged share was $0.17 and $0.37 for the years ended

                                                      


 

 

December 31, 2020 and 2019, respectively, based on non-GAAP fully exchanged weighted-average shares of 70.2 million and 53.4 million for the years ended December 31, 2020 and 2019, respectively.

 


 

                                                      


 

vTv Therapeutics Inc.

Condensed Consolidated Balance Sheets

(in thousands)

 

 

December 31,

 

 

September 30,

 

 

2020

 

 

2020

 

 

 

 

 

 

(Unaudited)

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

5,747

 

 

$

1,827

 

Accounts receivable, net

 

158

 

 

 

14

 

Prepaid expenses and other current assets

 

939

 

 

 

1,306

 

Current deposits

 

371

 

 

 

531

 

Total current assets

 

7,215

 

 

 

3,678

 

Property and equipment, net

 

367

 

 

 

389

 

Operating lease right-of-use assets

 

482

 

 

 

499

 

Long-term investments

 

6,725

 

 

 

2,480

 

Total assets

$

14,789

 

 

$

7,046

 

Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable and accrued expenses

$

6,120

 

 

$

5,747

 

Operating lease liabilities

 

155

 

 

 

149

 

Current portion of contract liabilities

 

31

 

 

 

31

 

Current portion of notes payable

 

84

 

 

 

2,369

 

Total current liabilities

 

6,390

 

 

 

8,296

 

Contract liabilities, net of current portion

 

1,009

 

 

 

1,017

 

Operating lease liabilities, net of current portion

 

676

 

 

 

717

 

Warrant liability, related party

 

2,871

 

 

 

2,715

 

Other liabilities

 

50

 

 

 

82

 

Total liabilities

 

10,996

 

 

 

12,827

 

Commitments and contingencies

 

 

 

 

 

 

 

Redeemable noncontrolling interest

 

83,895

 

 

 

45,591

 

Stockholders’ deficit:

 

 

 

 

 

 

 

Class A Common Stock

 

541

 

 

 

492

 

Class B Common Stock

 

232

 

 

 

232

 

Additional paid-in capital

 

209,161

 

 

 

201,243

 

Accumulated deficit

 

(290,036

)

 

 

(253,339

)

Total stockholders’ deficit attributable to vTv Therapeutics Inc.

 

(80,102

)

 

 

(51,372

)

Total liabilities, redeemable noncontrolling interest and stockholders’ deficit

$

14,789

 

 

$

7,046

 

 


                                                      


 

vTv Therapeutics Inc.

Condensed Consolidated Statements of Operations - Unaudited

(in thousands, except per share data)

 

 

Three Months Ended

 

 

December 31, 2020

 

 

September 30, 2020

 

Revenue

$

6,399

 

 

$

7

 

Operating expenses:

 

 

 

 

 

 

 

Research and development

 

2,534

 

 

 

1,768

 

General and administrative

 

2,035

 

 

 

1,071

 

Total operating expenses

 

4,569

 

 

 

2,839

 

Operating income/(loss)

 

1,830

 

 

 

(2,832

)

Interest expense

 

(67

)

 

 

(235

)

Other (expense) income, net

 

(156

)

 

 

814

 

Loss before income taxes and noncontrolling interest

 

1,607

 

 

 

(2,253

)

Income tax provision

 

 

 

 

 

Net loss before noncontrolling interest

 

1,607

 

 

 

(2,253

)

Less:  net income/(loss) attributable to noncontrolling interest

 

481

 

 

 

(720

)

Net income/(loss) attributable to vTv Therapeutics Inc.

$

1,126

 

 

$

(1,533

)

Net income/(loss) attributable to vTv Therapeutics Inc. common shareholders

$

1,126

 

 

$

(1,533

)

 

 

 

 

 

 

 

 

Net income/(loss) per share:

 

 

 

 

 

 

 

Basic net income/(loss) per share of vTv Therapeutics Inc. Class A

   Common Stock

$

0.02

 

 

$

(0.03

)

Diluted net income/(loss) per share of vTv Therapeutics Inc. Class A

   Common Stock

$

0.02

 

 

$

(0.03

)

 

 

 

 

 

 

 

 

Weighted average shares used in calculating:

 

 

 

 

 

 

 

Basic net income/(loss) per share of vTv Therapeutics Inc. Class A

   Common Stock

 

51,133,609

 

 

 

48,238,285

 

Diluted net income/(loss) per share of vTv Therapeutics Inc. Class A

   Common Stock

 

74,397,085

 

 

 

48,238,285

 


                                                      


 

vTv Therapeutics Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

 

 

Three Months Ended December 31,

 

 

 

 

For the Year Ended December 31,

 

 

2020

 

 

2019

 

 

 

 

2020

 

 

2019

 

 

(Unaudited)

 

 

 

 

 

 

Revenue

$

6,399

 

 

$

7

 

 

 

 

$

6,414

 

 

$

2,764

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

2,534

 

 

 

4,406

 

 

 

 

 

11,015

 

 

 

15,119

 

General and administrative

 

2,035

 

 

 

1,989

 

 

 

 

 

7,251

 

 

 

8,537

 

Total operating expenses

 

4,569

 

 

 

6,395

 

 

 

 

 

18,266

 

 

 

23,656

 

Operating income/(loss)

 

1,830

 

 

 

(6,388

)

 

 

 

 

(11,852

)

 

 

(20,892

)

Interest income

 

 

 

 

12

 

 

 

 

 

12

 

 

 

53

 

Interest expense

 

(67

)

 

 

(283

)

 

 

 

 

(692

)

 

 

(1,827

)

Other (expense) income, net

 

(156

)

 

 

(223

)

 

 

 

 

(270

)

 

 

828

 

Income/(loss) before income taxes and noncontrolling

   interest

 

1,607

 

 

 

(6,882

)

 

 

 

 

(12,802

)

 

 

(21,838

)

Income tax provision

 

 

 

 

 

 

 

 

 

 

 

 

100

 

Net income/(loss) before noncontrolling interest

 

1,607

 

 

 

(6,882

)

 

 

 

 

(12,802

)

 

 

(21,938

)

Less:  net income/(loss) attributable to noncontrolling

   interest

 

481

 

 

 

(2,483

)

 

 

 

 

(4,303

)

 

 

(8,894

)

Net income/(loss) attributable to vTv Therapeutics Inc.

$

1,126

 

 

$

(4,399

)

 

 

 

$

(8,499

)

 

$

(13,044

)

Net income/(loss) attributable to vTv Therapeutics Inc.

   common shareholders

$

1,126

 

 

$

(5,033

)

 

 

 

$

(8,499

)

 

$

(17,913

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income/(loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income/(loss) per share of vTv Therapeutics

   Inc. Class A Common Stock

$

0.02

 

 

$

(0.13

)

 

 

 

$

(0.18

)

 

$

(0.59

)

Diluted net income/(loss) per share of vTv

   Therapeutics Inc. Class A Common Stock

$

0.02

 

 

$

(0.13

)

 

 

 

$

(0.18

)

 

$

(0.59

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used in calculating:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income/(loss) per share of vTv Therapeutics

   Inc. Class A Common Stock

 

51,133,609

 

 

 

37,955,449

 

 

 

 

 

47,137,917

 

 

 

30,292,030

 

Diluted net income/(loss) per share of vTv

   Therapeutics Inc. Class A Common Stock

 

74,397,085

 

 

 

37,955,449

 

 

 

 

 

47,137,917

 

 

 

30,292,030

 

 

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and inflammatory disorders, including psoriasis. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), renal disease, and primary mitochondrial myopathy.

 

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our

                                                      


 

strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

 

Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the U.S. (“GAAP”), we use non-GAAP adjusted net income/(loss) per fully exchanged share, which is a non-GAAP financial measure. Non-GAAP adjusted net loss per fully exchanged share adjusts the net loss attributable to vTv common shareholders for the impact of adjustments related to outstanding warrants, share-based compensation expense and the portion of net loss attributable to the noncontrolling interest. It also assumes the exchange of all the Class B common stock of vTv Therapeutics Inc. and an equal number of non-voting common units of vTv Therapeutics LLC (“vTv Units”) for shares of Class A common stock of vTv Therapeutics Inc. We believe that this measure provides useful information to investors as it eliminates the variability of non-controlling interest resulting from the exchanges of Class B common stock and vTv Units into Class A common stock and other items of a non-cash nature. This measure is not intended to be considered in isolation or as a substitute for, or superior to, financial measures prepared and presented in accordance with GAAP.

 

The following is a reconciliation of non-GAAP adjusted net loss per fully exchanged share, basic and diluted to its most directly comparable GAAP measure, net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted and the computation of the components of this non-GAAP measure:

 

                                                      


 

 

Three Months Ended

 

 

December 31, 2020

 

 

September 30, 2020

 

Numerator:

 

 

 

 

 

 

 

Net income/(loss) attributable to vTv Therapeutics Inc. common shareholders

$

1,126

 

 

$

(1,533

)

Other income - related party

 

(156

)

 

 

814

 

Share-based compensation expense

 

272

 

 

 

171

 

Deemed distribution to related party

 

 

 

 

 

Reallocation of net income attributable to noncontrolling

   interest from the assumed exchange of Class B shares (1)

 

481

 

 

 

(720

)

Adjusted net income/(loss) before noncontrolling interest

$

1,723

 

 

$

(1,268

)

Denominator:

 

 

 

 

 

 

 

Weighted-average number of vTv Therapeutics Inc.

   Class A Common Stock, diluted

 

74,397,085

 

 

 

48,238,285

 

Assumed exchange of Class B Common Stock (1)

 

 

 

 

23,094,221

 

Adjusted proforma fully exchanged weighted-average

   shares of Class A common stock outstanding, diluted

 

74,397,085

 

 

 

71,332,506

 

Adjusted net income/(loss) per fully exchanged share, diluted

$

0.02

 

 

$

(0.02

)

 

 

Three Months Ended December 31,

 

 

Twelve Months Ended December 31,

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income/(loss) attributable to vTv Therapeutics Inc. common shareholders

$

1,126

 

 

$

(5,033

)

 

$

(8,499

)

 

$

(17,913

)

Other income - related party

 

(156

)

 

 

(223

)

 

 

(270

)

 

 

827

 

Share-based compensation expense

 

272

 

 

 

423

 

 

 

1,009

 

 

 

1,518

 

Deemed distribution to related party

 

 

 

 

634

 

 

 

 

 

 

4,869

 

Reallocation of net income attributable to noncontrolling

   interest from the assumed exchange of Class B shares (1)

 

481

 

 

 

(2,483

)

 

 

(4,303

)

 

 

(8,894

)

Adjusted net income/(loss) before noncontrolling interest

$

1,723

 

 

$

(6,682

)

 

$

(12,063

)

 

$

(19,593

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average number of vTv Therapeutics Inc.

   Class A Common Stock, diluted

 

74,397,085

 

 

 

37,955,449

 

 

 

47,137,917

 

 

 

30,292,030

 

Assumed exchange of Class B Common Stock (1)

 

 

 

 

23,094,221

 

 

 

23,094,221

 

 

 

23,094,221

 

Adjusted proforma fully exchanged weighted-average

   shares of Class A common stock outstanding,

   diluted

 

74,397,085

 

 

 

61,049,670

 

 

 

70,232,138

 

 

 

53,386,251

 

Adjusted net income/(loss) per fully exchanged share,

   diluted

$

0.02

 

 

$

(0.11

)

 

$

(0.17

)

 

$

(0.37

)

 

 

(1)

Assumes the exchange of all outstanding Class B common stock, resulting in the inclusion of shares of Class B common stock in the weighted average share count, if not already considered, and the elimination of the noncontrolling interest and recognition of the net income attributable to noncontrolling interests.

 

 

Contacts

Investors:

Corey Davis
LifeSci Advisors
CDavis@LifeSciAdvisors.com

 

                                                      


 

or


Media:

PR@vtvtherapeutics.com 

 

                                                      

View differences made from one to another to evaluate Vtv Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Vtv Therapeutics Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account